1. Home
  2. FT vs IPHA Comparison

FT vs IPHA Comparison

Compare FT & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Franklin Universal Trust

FT

Franklin Universal Trust

HOLD

Current Price

$8.32

Market Cap

199.8M

Sector

Finance

ML Signal

HOLD

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

N/A

Current Price

$1.63

Market Cap

160.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FT
IPHA
Founded
1988
1999
Country
United States
France
Employees
N/A
174
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
199.8M
160.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
FT
IPHA
Price
$8.32
$1.63
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$5.00
AVG Volume (30 Days)
66.5K
15.7K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
7.85%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$28.31
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.71
$1.57
52 Week High
$8.35
$2.63

Technical Indicators

Market Signals
Indicator
FT
IPHA
Relative Strength Index (RSI) 63.74 41.03
Support Level $7.79 $1.60
Resistance Level $8.35 $1.88
Average True Range (ATR) 0.08 0.08
MACD -0.00 -0.01
Stochastic Oscillator 61.76 13.67

Price Performance

Historical Comparison
FT
IPHA

About FT Franklin Universal Trust

Franklin Universal Trust is a closed-end management investment company focused on providing high current income while preserving capital. Its secondary objective is to achieve income growth through dividend increases and capital appreciation. The fund invests in two asset classes: high-yield bonds and utility stocks. It applies fundamental research to build a diversified high-yield bond portfolio and targets utility companies with attractive dividend yields and a history of increasing dividends.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

Share on Social Networks: